- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07792694
Predict Arrhythmia Risk Using Intelligent Software (PARIS)
Artificial Intelligence-based Prediction and Detection of Critical Arrhythmias in Acute Cardiac Illness.
Cardiac arrhythmias frequently occur in patients admitted to the Coronary Care Unit (CCU). The majority of these patients are treated for an acute myocardial infarction, which carries an increased risk of life-threatening arrhythmias such as ventricular tachycardia (VT) or ventricular fibrillation (VF). This risk is one of the reasons these patients are monitored for 48 hours after a myocardial infarction, in accordance with the guidelines of the European Society of Cardiology (ESC) for acute coronary syndrome. Other arrhythmias, such as asystole, atrial fibrillation, or atrioventricular block, also occur in CCU patients. These arrhythmias are recorded on the electrocardiogram (ECG) monitor in the CCU and trigger an alarm for healthcare staff. However, in order to apply this alarming with sufficient sensitivity, many false positive alarms are also produced, which increases the workload for nurses (alarm fatigue) and undermines patient well-being.
This study will investigate whether Artificial Intelligence (AI) models, using continuous ECG data, can help improve the prediction of patients at risk of a life-threatening cardiac arrhythmia. Firstly, this study will aim to predict patients at risk of VT/VF in both the short term (30 minutes) and long term (1 day) in patients under continuous telemetric monitoring. This prediction facilitates timely intervention by the team in the short term, and in the long term, the safe transfer of a patient to a lower-complexity ward or earlier safe discharge of a patient. Secondly, this study will aim for improved detection to reduce the number of false negative alarms and thereby reduce alarm fatigue.
The performance of these AI models can be evaluated through this retrospective observational study. Patients aged 18 years or older who have been admitted with acute cardiac disease will be included. The primary objective of this study will be to evaluate the performance of AI models that detect and predict critical arrhythmias in the short and long term, using ECG data obtained via the monitoring system.
Descripción general del estudio
Estado
Descripción detallada
Primary objective:
Assessment of the performances of AI models in identifying patients at risk of sustained VT and VF from bedside monitor ECG in different timeframes:
- 30-minute prediction model
- 1-day prediction model
Secondary objectives:
• Assessment of potential healthcare savings if the AI model in would be used in clinical practice, such as CCU length-of-stay (CCU-LOS), hospital length-of-stay and associated costs
Exploratory objectives:
- Real time and continuous detection of events for alarming
- Prediction of other types of arrhythmias (e.g., Atrial fibrillation (AF), atrioventricular block, severe brady-arrhythmia) using in hospital ECG monitoring.
- Identification of clinical risk factors for sustained VT and/or VF
- Exploration of development and assessment of new AI models using new (clinical) input
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Maud E Kortman, M.D.
- Número de teléfono: 040 239 9111
- Correo electrónico: maud.kortman@catharinaziekenhuis.nl
Copia de seguridad de contactos de estudio
- Nombre: Luuk C Otterspoor, Dr. M.D.
- Correo electrónico: luuk.otterspoor@catharinaziekenhuis.nl
Ubicaciones de estudio
-
-
North Brabant
-
Eindhoven, North Brabant, Países Bajos, 5623 EJ
- Reclutamiento
- Catharina Hospital Eindhoven
-
Contacto:
- Maud E Kortman, M.D.
- Número de teléfono: 040 239 9111
- Correo electrónico: maud.kortman@catharinaziekenhuis.nl
-
Investigador principal:
- Luuk C Otterspoor, Dr. M.D.
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion criteria:
- Patients admitted from 1/1/2023*
- Patients aged 18 years or older
- Admitted for acute cardiac illness or after elective cardiac procedures
- Who are on ECG monitoring in the CCU, ICU or ward
Patients for whom continuous waveform ECG data have been routinely stored.
- Continuous waveform ECG data has been routinely stored in the CZE since 1/1/2023 on the ICU, since 1/12/2025 on the CCU and on the ward it has yet to be implemented. As our project utilizes this continuous ECG data, it will only include patients for whom this data is available.
Exclusion Criteria:
- Patients who expressed their preference for not having their data used for scientific research or to improve quality of care in the opt-out program of the CZE.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Adult patients admitted for acute cardiac illness/elective cardiac procedures on ECG monitoring
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Occurrence of sustained ventricular tachycardia or ventricular fibrillation
Periodo de tiempo: During admission
|
The primary outcome of the study is the occurrence of sustained ventricular tachycardia (VT) (monomorphic and polymorphic with a heartrate > 100 bpm and duration > 30 seconds or with hemodynamic compromise such as fainting or need for resuscitation) or ventricular fibrillation.
(Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Secondary outcome measure
Periodo de tiempo: During admission
|
- A 'textbook' outcome (no adverse events) (Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
|
Secondary Outcome Measure
Periodo de tiempo: during admission
|
- In-hospital onset and offset of cardiac arrhythmias (e.g.
atrial fibrillation, atrio-ventricular block or severe tachy- or bradyarrhythmia, non-sustained VT).
(Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
during admission
|
|
Secondary outcome measure
Periodo de tiempo: During admission
|
- In hospital death/cardiovascular in-hospital death (include cause if available) (Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
|
Secondary outcome measure
Periodo de tiempo: During admission
|
- Pulseless electrical activity (PEA) and asystole (Binary outcome measure 0 = no event during admission, 1 = event during admission)
|
During admission
|
|
Performance of AI prediction model
Periodo de tiempo: During admission
|
Discrimination of AI prediction model expressed with Area Under the Receiver Operating Characteristic curve (AUROC), Area Under the Precision-Recall Curve (AUPRC), sensitivity, specificity, (Positive Predictive Value) PPV and (Negative Predictive Value) NPV
|
During admission
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Luuk C Otterspoor, Dr. M.D., Catharina Ziekenhuis Eindhoven
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- nWMO-2025.186
- project code 24PPS046 (Otro número de subvención/financiamiento: National collaboration: Holland High Tech, Eindhoven University of Technology, Catharina Hospital Eindhoven, Philips)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .